Allogene Therapeutics (ALLO) Operating Leases (2018 - 2026)

Allogene Therapeutics has reported Operating Leases for 9 years, with the latest figure at $81.1 million in Q1 2026.

• Quarterly Operating Leases fell 8.85% year-over-year to $81.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $81.1 million (down 8.85% YoY) and the FY2025 annual result came in at $83.3 million, down 8.27% from the prior year.
• Operating Leases fell to $81.1 million in Q1 2026 per ALLO's latest filing, from $83.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $98.2 million in Q2 2022 and troughed at $69.0 million in Q1 2022.
• A 5-year average of $88.1 million and a median of $90.1 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases jumped 91.83% in 2022, then decreased 15.89% in 2025.
• Over 5 years, Operating Leases stood at $95.1 million in 2022, then dropped by 0.0% to $95.1 million in 2023, then fell by 4.59% to $90.8 million in 2024, then fell by 8.27% to $83.3 million in 2025, then fell by 2.64% to $81.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $81.1 million, $83.3 million, and $77.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.